Kornimate/medical-research-clean huggingface dataset:
empowering hispanic patients' lung cancer screening uptake (empower latinx)

Conditions: Lung Cancer

Summary: the hispanic/latinx community (hereafter hispanic) is the country's second-largest racial/ethnic group, accounting for 19.1% of the total population. however, they remain one of the most underserved populations with suboptimal access to healthcare and screening services due to low income, lack of health insurance, perceived discrimination, language barriers, and limited health literacy. lung cancer is the leading cause of cancer related mortality with 1.8 million annual deaths worldwide, with hispanic patients known to have lower survival rates compared with non-hispanic whites. lung cancer screening (lcs) with low dose computed tomography (ldct) decreases this mortality rate of lung cancer by 20%. yet many latinx patients who are eligible for lung cancer screening are still falling through the cracks which prevents patients the ability to detect lung cancer early. this study will test and compare the effect of a multi-level intervention on ordering ldct within 4 months after patient enrollment to those in an enhanced usual care. our proposed intervention includes: * primary care provider notifications of patients' lcs eligibility; * patients' education; * patients' referral to financial navigation resources; * patients' reminder to discuss lcs during primary care provider (pcp) visit.


Eligibility criteria:
inclusion criteria: * aged 50- 80 years of age. * be able to speak english and spanish * must have a primary care provider. * history of 20-pack year smoking history ( based on survey self-report) * current smoker or a former smoker who has quit smoking within the last 15 years (based on survey self-report) * resident of california exclusion criteria: * prior history of lung cancer * chest ct for any reason in the last 12 months based on self-report and uci emr * history of alzheimer's disease or dementia

Keywords: lung cancer screening multi-level intervention
cognitive processes study in obese women with and without eating disorders

Conditions: Hyperalimentation and Obesity

Summary: the p300 is one of the cognitive wave of the event-related potential (erp) that is used to investigate the cognitive process. the p300 component are accepted as electro-physiological markers of neuropsychiatric disorders like alcoholism or drug addiction. recent scientific data suggest that eating disorders, leading to weight gain and obesity, will be similar of those of drug addiction: it is the incentive sensitization theory that implicates the dopaminergic reward system. the aim of this cross-sectional study is to investigate the alteration of p300 auditory erp in obese women with eating disorders in comparison with obese and lean women without eating disorders.


Eligibility criteria:
inclusion criteria: * women * aged from 20 to 55 years * fasting glycemia under 7mmol/l * lean women : women with bmi from 18.5 to 24.5 and disinhibition score to three-factor eating questionnaire (tfeq)lower or equal to 8 * obese women without eating disorders : women with bmi higher or equal to 35 and disinhibition score to tfeq lower or equal to 8 * obese women with eating disorders : women with bmi higher or equal 35 and disinhibition score to tfeq strictly higher to 8 exclusion criteria: * subject not in compliance with the recommendations of french national law in force * medical history of diabetes and surgery history of obesity * drug use that could affect the erp recording * hospital anxiety and depression scale : evaluation subscale (anxiety and/or depression) strictly higher to 11

Keywords: obesity hyperalimentation event-related potential p300
pharmacokinetics of inhaled mannitol in cystic fibrosis patients

Conditions: Cystic Fibrosis

Summary: the general objective of the study is to estimate the systemic pharmacokinetics of mannitol after single and multiple dosing of idpm 400 mg to adult and paediatric cystic fibrosis patients.


Eligibility criteria:
inclusion criteria: * have given written informed consent to participate in this study in accordance with local regulations * have a confirmed diagnosis of cystic fibrosis (sweat test and/or genotype) * be aged \>6 years (6-11 for paediatrics, 12-17 for adolescents and 18 years for adults) * have fev1 \> 30 % and \< 90% predicted exclusion criteria: * be investigators, site personnel directly affiliated with this study, or their immediate families. immediate family is defined as a spouse, parent, child or sibling, whether biologically or legally adopted. * be considered "terminally ill" or listed for lung transplantation * have had a lung transplant * be using nebulised hypertonic saline * have had a significant episode of haemoptysis (\> 60 ml) in the three months prior to enrolment * have had a myocardial infarction in the three months prior to enrolment * have had a cerebral vascular accident in the three months prior to enrolment * have had major ocular surgery in the three months prior to enrolment * have had major abdominal, chest or brain surgery in the three months prior to enrolment * have a known cerebral, aortic or abdominal aneurysm * be breast feeding or pregnant, or plan to become pregnant while in the study * be using an unreliable form of contraception (female patients at risk of pregnancy only) * be participating in another investigative drug study, parallel to, or within 4 weeks of study entry (except inhaled mannitol) * not able to maintain a mannitol free diet from day -2 until day 8 of the treatment phase. * have a known allergy to mannitol * be using beta blockers * have uncontrolled hypertension - systolic blood pressure \> 190 and / or diastolic blood pressure \> 100 * have a condition or be in a situation which in the investigator's opinion may put the subject at significant risk, may confound results or may interfere significantly with the patient's participation in the study * be mtt positive.
the effectiveness of buccal infiltration only using articaine for extraction of mandibular molar

Conditions: Pain

Summary: the goal of this clinical trial, is to test out the efficacy of using articaine only as a local anesthesia as buccal infiltration to extract lower molar teeth. study will be performed in patients visiting riyadh elm university clinics seeking extraction of lower molars bilaterally, in each visit one molar tooth will be extracted using ariticaine and the second visit with lidocaine, pain level will be monitored and documented. this study may be helpful in providing scientific information to the oral maxillofacial surgeons which will assist them in choosing the best local anesthetic agent, and possibly substituting using inferior alveolar nerve block with infiltration only when extracting the mandibular posterior teeth.

this is a double-blind, randomized clinical trial, which will involve 40 patients visiting the out-patient department of oral and maxillofacial surgery. for each patient, one mandibular molar will be extracted from right as well as left side, with one side being anesthetized using 4% articaine with 1:100,000 epinephrine and other with 2% lidocaine with 1:100,000 epinephrine buccal infiltration only. evaluation and comparison will be done on the basis of pain prevalence exhibited by the patients while extraction.

Eligibility criteria:
inclusion criteria: * male and female patients * patients with age more than 18 years * patients indicated for at least one mandibular molar extraction * patients with the ability to fill the questionnaire exclusion criteria: * patients with abscess or any lesion, which may affect the local anesthesia provision. * patients with stage iii mobile teeth * patients with a history of medical conditions such as diabetes mellitus, heart disease, pregnancy, allergy or renal disease * patients who are not able to give an informed consent or are not agreeing to take part in this study
cost efficacy evaluation of robot assisted radical prostatectomy

Conditions: Prostate Cancer

Summary: in this observational cost efficacy study, the investigator compare the laparoscopic radical prostatectomy (lrp) versus robotic-assisted laparoscopic prostatectomy (ralp). every cost of care that include hospitalization related or post operative medical consumption are obtained and recorded up to 5 years follow up. functional results (continence, potency, quality of life) are obtained through standardised questionnaires. carcinologic results are estimated by prostate specific antigen (psa) relapse and salvage treatments. economic evaluation will be made to estimate direct costs of the four postoperative year along with the incremental cost-effectiveness ratio (icer) per successful surgical treatment (preserved urinary continence and erectile function and psa \< 0.2).


Eligibility criteria:
inclusion criteria: * localized prostate cancer * gleason grade ≤ 3 + 4 * psa \< 15 ng / ml * stage ≤ t2b * eligible to receive laparoscopic radical prostatectomy * candidate bilateral or unilateral erectile preservation exclusion criteria: * patient at high risk of postoperative progression (psa\> 15 ng / ml; grade 5 predominant, clinical or radiological stage t3 * presenting erectile dysfunction (iief \< 22) * past history of urinary incontinence (\> grade 1 who) * body mass index \> 30

Keywords: clinically localized prostate cancer robotic-assisted prostatectomy laparoscopic prostatectomy erectile function ; cost efficacy study
cognitive behavior therapy (cbt) and mirror training for phantom limb pain

Conditions: Phantom Limb

Summary: the goal of this study is to test whether a combination of cognitive-behavior therapy and mirror training reduces phantom limb pain for veterans with amputations.

the proposed study is a randomized controlled trial designed to test whether cbt plus mirror therapy (cbt+mt) is superior to supportive care (sc) for treatment of phantom limb pain (plp) in amputees. the primary hypothesis is that cbt+ mt will lead to significantly greater reductions in plp compared to sc. secondary hypotheses will test whether cbt+mt also leads to significantly greater improvements in psychiatric symptoms, functioning, and quality of life than sc. eighty veterans from the san diego va healthcare system (sdvahs) will be recruited. all veterans will have a unilateral upper or lower limb amputation. all participants will complete an intake assessment prior to treatment randomization. the assessment will include measures of pain (phantom limb pain questionnaire, descriptive differential scale, mcgill pain questionnaire) psychiatric symptoms (patient health questionnaire, posttraumatic stress disorder checklist), psychiatric diagnosis (mini-international neuropsychiatric interview) and functioning (trinity amputation and prosthesis experiences scale, short form-36). participants will then randomized to either cbt+mt or sc. participants will complete pain and mood assessments weekly during treatment, and be retested on the full assessment battery at the end of treatment and 12 and 24 weeks posttreatment. the cbt+mt intervention will consist of 8 individual sessions of cbt, including psychoeducation, cognitive restructuring, relaxation training, and acceptance techniques. participants in the cbt+mt condition will also learn to use a mirror apparatus to reduce plp, and will receive a set of mirrors to use at home. the sc treatment will consist of the therapist meeting with the patient and using listening and reflection skills to discuss the patient's pain. the sc condition will have no pain education or skills training component. data analyses will use a repeated-measures anova approach to test whether the two conditions differ on change in the primary measure (phantom limb pain questionnaire) as well as in other pain, psychiatric symptom, functioning and quality of life measures. exploratory analyses will test whether patient variables and amputation characteristics predict treatment outcomes.

Eligibility criteria:
inclusion criteria: * adult (21or over) * unilateral amputation at or above wrist or ankle * phantom limb pain occurring at least weekly * living within 50 miles of a recruitment site (san diego, san francisco, or long beach vas). * able to read and speak english exclusion criteria: * current alcohol or drug dependence * active psychosis * medical problems that preclude participation * current enrollment in behavioral pain management

Keywords: cognitive therapy mirror training nondirective therapy veterans amputees
anterior and posterior approaches of suprascapular nerve block

Conditions: Shoulder Pain; Postoperative Pain; Diaphragmatic Paralysis; Subomohyoid Suprascapular Nerve Block; Anterior Suprascapular Nerve Block; Suprascapular Nerve Block

Summary: suprascapular nerve is a mixed motor and sensory peripheral nerve arising from the superior trunk of brachial plexus.the suprascapular nerve runs through the posterior triangle of the neck, anterior of the trapezius muscle and dorsal of the omohyoid muscle, in direction of the scapula. suprascapular nerve block is performed by anterior and posterior approach. posterior approach of the suprascapular nerve block has been shown for many years to provide effective analgesia in the shoulder region for the chronic and acute pain. there are studies showing that suprascapular block with anterior approach provides effective analgesia in shoulder arthroscopy. the aim of our study was to compare anterior and posterior approaches of suprascapular nerve block in terms of analgesic efficacy and patient safety.

this study is a prospective randomized clinical trial will be conducted between march 2022 and march 2023.participant will divide into two groups as participant who underwent suprascapular nerve block with the anterior approach and participant who underwent suprascapular nerve block with the posterior approach. bupivacaine 5 ml %0.5 will be injected both group. diaphragmatic thickness fraction will be evaluated with ultrasound left and right 7.-8. subcostal anterior axillary border with the participant with the semi-sitting position. diaphragmatic thickness fraction will measure before the block and after 30 minutes the surgery. participants will administered intravenous morphine patient controlled analgesia for 24 hours stay. the amount of opioid analgesics given in both groups will be determined (in mg). postoperative 4th, 6th, 12th, 24th hour visual analogue scale scores of the participants and opioid consumptions until that hours will be evaluated. an addition participant will be determined according to the surgery.

Eligibility criteria:
inclusion criteria: * patient who accepts to study protocol * scheduled for shoulder surgery * between the ages of 18 and 80 exclusion criteria: * patients with coagulopathy * patients with a history of local anesthetic drug allergy and toxicity * patients with advanced organ failure * patients with mental retardation * patients with infection present at the injection site * patients with diaphragm paralysis * pregnant patients

Keywords: shoulder pain nerve block diaphragmatic paralysis postoperative pain suprascapular block subomohyoid suprascapular block posterior suprascapular block anterior suprascapular block
study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with systemic sclerosis (ssc)-related interstitial lung disease (ild) (ssc-ild)

Conditions: Interstitial Lung Disease

Summary: this is a 2-part study with part a, a double-blind, randomized, placebo-controlled, poc study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with ssc-ild. the primary objective of the study is to evaluate the poc for efficacy in a population with ssc-ild. while improvement of ild is the outcome of interest, the study will also evaluate changes in the skin. after initial screening (up to 4 weeks), approximately 25 eligible participants will be randomized 2:2:1 to 1 of 2 active (experimental) dose arms or placebo, administered every 4 weeks up to and including week 20. part b is an optional open-label extension to part a in which participants can receive 450 mg efzofitimod every 4 weeks for 6 doses.


Eligibility criteria:
inclusion criteria: 1. diagnosis of ssc based on acr/ eular criteria (2013) 2. overall duration of ssc \< 84 months from the first non-raynaud symptom manifestation prior to day 1 3. hrct obtained at the screening visit or within the 3 months prior to screening consistent with ssc-ild (adjudicated by a central reader) and with pulmonary involvement \> 10% 4. clinical presentation at screening consistent with lcssc (up to 40% of patients) or dcssc 5. mmf of ≥ 2 gm/day (or equivalent doses of other mycophenolate based compounds) for 3 months prior to day 1 or when documented intolerance to mycophenolates (in discussion with the medical monitor): treatment with maximum tolerated dose of mmf is acceptable, if \< 2 gm/day, provided the cumulative duration of dosing has exceeded 3 months, or an adequate dose and duration of an alternate immunosuppressant with a stable dose for the 4 weeks prior to baseline is also allowed. exclusion criteria: 1. pulmonary disease with fvc %pred ≤ 45% or dlco %pred ≤ 30%; fev1/fvc ratio \< 0.7 2. participants with pulmonary artery hypertension on parenteral therapy or with clinical evidence of right heart failure 3. hrct obtained in the 3 months prior to screening consistent with other confounding pathology. 4. treatment with corticosteroids (\> 10 mg/day of prednisone or equivalent) within 2 weeks prior to day 1 5. treatment with more than 1 immunosuppressant (e.g., mmf, methotrexate \[mtx\], azathioprine \[aza\], or leflunomide) 6. any treatment in the 12 months prior to day 1 with any of the following: rituximab, intravenous immune globulin (ivig), tocilizumab, cyclophosphamide, pirfenidone, tyrosine-kinase inhibitors (e.g., imatinib, nilotinib, dasatinib) 7. rheumatic autoimmune disease other than ssc, is an active, heavy smoker of tobacco/nicotine-containing products 8. history of (anti-jo-1) anti-synthetase syndrome or jo-1 positive at screening

Keywords: ild ssc-ild interstitial lung disease lung inflammation fibrosis pulmonary function efzofitimod systemic sclerosis
a phase ii efficacy study in fistulizing crohn's disease patients

Conditions: Crohn's Disease

Summary: this study will assess the safety and efficacy of qax576 if patients with fistulizing crohn's disease.


Eligibility criteria:
inclusion criteria: * at least one draining enterocutaneous perianal fistula * diagnosis of crohn's disease (cd) must have been established for at least 6 months * at least one ineffective fistula treatment (but no previously failed anti-tnfα (tumour necrosis factor) antibody treatment) * patients should not suffer from any other health problems that may jeopardize their participation in the study. exclusion criteria: * current or recent (within 30 days of enrollment, or 5 half-lives of the compound, whichever is longer) use of anti-tnfα antibody treatment * active crohn's disease * recent or pending abdominal or ano-rectal surgery, particularly presence of stricture, or abscess, or retention for which surgery might be indicated * previously failed anti-tnfα antibody treatment * intercurrent bacterial or viral (intestinal) infection (serologically or microbiologically confirmed) other protocol-defined inclusion/exclusion criteria may apply

Keywords: crohn's disease fistula
effectiveness of tdcs for the treatment of functional dyspepsia

Conditions: Dyspepsia

Summary: functional dyspepsia is a very common disorder of great challenge to clinical management. a therapeutic targets is up-regulation of visceral pain threshold. the transcranial direct current stimulation (tdcs) is a novel therapy that pursues these properties, besides its safety and easy adherence. there is a great need of new treatments for functional dyspepsia. there is no current study evaluating tdcs for this disease.

functional dyspepsia is a high prevalent disease with substantial costs to health system. there are many available treatments, but disappointing results are reported in clinical trials. tdcs is a noninvasive, secure and painless technique of brain stimulation. it is delivered by a battery-operated device that transfers low intensity electrical current to all surface of the brain. then there is a modulation of cortical excitability and influence on central neurological functions. it has been reported its efficacy for the treatment of many diseases such as depression and chronic pain. impairment of central mechanisms of interpretation and threshold of pain are related to functional dyspepsia. therefore, tdcs may benefit dyspeptic patients. this study is a double blind randomized controled trial to test tdcs effectiveness on functional dyspepsia. seventy functional dyspeptic patients will be enrolled, being randomized to either tdcs or sham tdcs.

Eligibility criteria:
inclusion criteria: * functional dyspeptic patients according to rome iv criteria * clinical investigation reporting absence of organic causes of functional dyspepsia exclusion criteria * history of brain trauma, haemorrhage or ischemia * implantable devices such as pacemaker * alcohol or drug abuse * epilepsy * severe chronic disease * non-acceptance to sign up the term of consent.

Keywords: functional dyspepsia tdcs
structured treatment interruptions with or without pegylated interferon alpha for hiv-infected patients after prolonged viral suppression

Conditions: HIV Infections

Summary: the purpose of this study is to determine whether the adjunctional of interferon alfa to structured treatment interruptions correlated with a long time off treatment in hiv-1 infection.

the limitations of the drugs used against hiv include their toxicity, their tolerability, their propensity to induce resistance when not taken with absolute regularity and their cost. treatment interruption in patients receiving antiretroviral treatment in the setting of chronic infection is associated with viral rebound and rapid cd4 t cell decrease conducting to antiretroviral therapy restart. in patients with high cd4+ cell counts (patients receiving treatment of chronic infection with controlled viremia and patients who are receiving highly active antiretroviral therapy (haart) now in whom treatment would not have been started based on current guidelines), the investigators evaluated whether the adjunctional of interferon alfa 2b to 3 structured treatment interruptions correlated with a long time off treatment. haart was interrupted for 4 weeks, restarted and continued for 12 weeks. after 3 such cycles treatment was indefinitely suspended 48 weeks after study entry. another aim of this study was to assess the immunological and virological factors associated with the duration of treatment interruption (proviral hiv dna at baseline and during follow-up, plasma hiv rna at baseline and during follow-up, cd4 t cell and cd8 t cell hiv specific responses at baseline and after 6 months of interruption).

Eligibility criteria:
inclusion criteria: * males and non pregnant females * confirmed laboratory diagnosis of hiv infection * have been on the same continuous haart regimen for at least 6 months prior to inclusion * viral load below 50 cp/ml for at least 6 months * cd4 over 350 cells/mm3 * previous viral load over 10000 cp/ml in their history * no cd4 cell count under 100/mm3 in their history * for women of reproductive ages: negative serum pregnancy test * signed written consent to participate. exclusion criteria: * already had interferon or interleukin-2 (il-2) * positive hepatitis c virus (hcv) pcr * under treatment with abacavir during screening * serious psychiatric history, suicide attempt, or severe depression * history of thyroid abnormality * opportunistic infection ongoing * lymphoma or kaposi's sarcoma (ks) under chemotherapy

Keywords: interferon alfa-2b hiv infections